2-n-Pentylpyrimidin | 61327-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-n-Pentylpyrimidin
• 英文别名: 2-pentyl-pyrimidine；2-Pentylpyrimidine
• CAS: 61327-66-0
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: NIQYHKFKPNBQPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,3-丙二胺 以21%的产率得到
  参考文献：
  名称：

  TSUCHIYA MICHIHIRO; MORITA SHUSHI; TSUKAMOTO TOYHISA; OKADA JUTARO, YAKUGAKU DZASSI. JAKUGAKU ZASSNI. J. PHARM. SOS. JAR., 1976, 96, NO 8, 10+

  摘要：

  DOI：

文献信息

• Use of N-oxide compounds in coupling reactions
  申请人：Fagnou Keith

  公开号：US20080132698A1

  公开（公告）日：2008-06-05

  Metal-catalyzed coupling process comprising reacting a compound of general formula 1 with a compound A-X, to obtain a compound of general formula 2, which may further be converted to a compound of general formula 3

  金属催化偶联过程包括将一般式1的化合物与化合物A-X反应，得到一般式2的化合物，该化合物可能进一步转化为一般式3的化合物。
• [EN] NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE<br/>[FR] COMPOSÉS ACTIVANT NURR1:RXR POUR LE TRAITEMENT SIMULTANÉ DES SYMPTÔMES ET DE LA PATHOLOGIE DE LA MALADIE DE PARKINSON
  申请人：VASSILATIS DEMETRIOS K

  公开号：WO2017068070A1

  公开（公告）日：2017-04-27

  The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.

  这项发明提供了一系列取代芳基嘧啶化合物，并利用这些化合物作为治疗剂来治疗或预防神经退行性疾病，包括帕金森病。该发明的化合物还能够治疗这些疾病的症状，因此代表了一种新的治疗方式，用于改善慢性和急性病症。该发明的化合物能够选择性地增强Nurr1:RXRα异源二聚体的活性，并能够治疗与异常Nurr1:RXRα功能相关的疾病或病症。该发明还提供了通过给予Nurr1:RXRα激活剂来治疗神经退行性疾病的方法。
• 5-HT2B receptor antagonists
  申请人：——

  公开号：US20040010022A1

  公开（公告）日：2004-01-15

  The present invention relates to compounds of formula I: 1 wherein one of R 1 and R 4 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl; and the other of R 1 and R 4 is an optionally substituted C 9-14 aryl group; R 2 and R 3 are either: (i) independently selected from H, R, R′, SO 2 R, C(═O)R, (CH 2 ) n NR 5 R 6 , where n is from 1 to 4 and R 5 and R 6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl, and R′ is optionally substituted phenyl-C 1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT 2B receptor.

  本发明涉及公式I的化合物： 1 其中R 1 和R 4 之一选自由H、以及可选地取代的C 1-6 烷基、C 3-7 环烷基、C 3-7 环烷基-C 1-4 烷基和苯基-C 1-4 烷基组成的组；R 1 和R 4 的另一个是可选地取代的C 9-14 芳基基团；R 2 和R 3 是： (i)独立地选自H、R、R′、SO 2 R、C(═O)R、(CH 2 ) n NR 5 R 6 ，其中n是从1到4，R 5 和R 6 独立地选自H和R，其中R是可选地取代的C 1-4 烷基，R′是可选地取代的苯基-C 1-4 烷基，或 (ii)与它们连接的氮原子一起，形成一个可选地取代的C 5-7 杂环基团；以及它们作为药物的使用，特别用于治疗通过5-HT 2B 受体的拮抗作用减轻的状况。
• ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF
  申请人：Li Song

  公开号：US20110009427A1

  公开（公告）日：2011-01-13

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ)-associated diseases and risk factors.

  本发明涉及一种具有式(I)的化合物，或其药学上可接受的盐或溶剂。式(I)中的各种取代基如规范中所定义。本发明还涉及包括式(I)化合物的药物组合物，式(I)化合物的制备方法，以及利用该化合物制备用于治疗和/或预防人类过氧化物酶体增殖物激活受体δ(hPPARδ)相关疾病和危险因素的药物的用途。
• [EN] AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON<br/>[FR] COMPOSÉS D'AMINO-PYRIMIDINE EN TANT QU'INHIBITEURS DE TBKL ET OU D'IKK EPSILON
  申请人：MYREXIS INC

  公开号：WO2011046970A1

  公开（公告）日：2011-04-21

  The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).

  这项发明涉及抑制TBK1和/或IKK epsilon的某些氨基嘧啶化合物，因此可能在治疗炎症、癌症、感染性休克和/或原发性开角青光眼（POAG）中找到应用。